OncoMatch/Clinical Trials/NCT07275073
JMT106 Injection in the Treatment of Advanced Solid Tumors
Is NCT07275073 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies JMT106 for advanced solid tumor.
Treatment: JMT106 — This study is the first-in-human Phase I study of JMT106 injection, comprising two phases: Dose escalation with backfill and cohort expansion. The planned study population consists of subjects with advanced solid tumors. The objective is to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of JMT106 injection as monotherapy in participants with advanced solid tumors
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Non-Small Cell Lung Carcinoma
Hepatocellular Carcinoma
Disease stage
Metastatic disease required
advanced solid tumor; At least one measurable lesion according to RECIST 1.1 criteria
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-GPC3 therapy
Previous treatment with anti-GPC3 therapy
Cannot have received: antitumor therapy (chemotherapy, targeted therapy, immunotherapy, etc.) or investigational intervention
Exception: within 4 weeks or 5 half-lives (whichever is shorter) before the first dose, or traditional Chinese medicine with antitumor indications within 14 days prior
Any antitumor therapy (chemotherapy, targeted therapy, immunotherapy, etc.) or investigational intervention within 4 weeks or 5 half-lives (whichever is shorter) before the first dose, or traditional Chinese medicine with antitumor indications within 14 days prior
Lab requirements
Blood counts
ANC ≥1.5×10⁹/L; Platelets ≥90×10⁹/L; Hemoglobin ≥90 g/L
Kidney function
Creatinine clearance (Ccr) >50 mL/min (Cockcroft-Gault formula)
Liver function
Total bilirubin ≤1.5×ULN (≤3×ULN for liver metastases or hepatocellular carcinoma); ALT and AST ≤2.5×ULN (≤5×ULN for liver metastases or hepatocellular carcinoma)
Sufficient organ function, with laboratory tests meeting the following criteria (no blood transfusion or hematopoietic growth factor treatment within 14 days): ... see above for details
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify